We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Nexstim

Pilot studies lift off in depression and pain

Lighthouse | 25 September 2020

Allergy Therapeutics

Strong performances against strategic goals

Initiation | 23 September 2020

Hutchison China MediTech

ESMO 2020: SANET-p delivers further positive suru data

Update | 22 September 2020

MaxCyte

In the vanguard of next-generation cell and gene therapies

Update | 21 September 2020

Futura Medical

MED3000 on course for OTC approval in Europe and US

Update | 16 September 2020

Redx Pharma

Proof is in the pipeline

Initiation | 14 September 2020

Mereo BioPharma

TIGIT programme starts the next chapter

Outlook | 02 September 2020

Scancell

UKRI awards funding for COVID-19 trial

Lighthouse | 27 August 2020

Nexstim

Mapping out the 2020-24 corporate strategy

Update | 18 August 2020

MaxCyte

Broadened scope for current MCY-M11 Phase I study

Lighthouse | 18 August 2020
211 results found.